본문으로 건너뛰기
← 뒤로

Antrocinol-mediated downregulation of ATG5 induces autophagy-dependent cell death and activates the unfolded protein response through PERK/CHOP signaling in lenvatinib-resistant hepatocellular carcinoma cells.

European journal of pharmacology 2025 Vol.1006() p. 178115

Lai SW, Cheng YC, Hsieh MS, Kuo KT, Yadav VK, Tzeng YM, Yeh CT, Tsai TY

📝 환자 설명용 한 줄

[BACKGROUND] This study seeks to provide preclinical evidence demonstrating the potential of Antrocinol, a derivative of antrocin derived from the active compound of Antrodia cinnamomea, as a promisin

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Lai SW, Cheng YC, et al. (2025). Antrocinol-mediated downregulation of ATG5 induces autophagy-dependent cell death and activates the unfolded protein response through PERK/CHOP signaling in lenvatinib-resistant hepatocellular carcinoma cells.. European journal of pharmacology, 1006, 178115. https://doi.org/10.1016/j.ejphar.2025.178115
MLA Lai SW, et al.. "Antrocinol-mediated downregulation of ATG5 induces autophagy-dependent cell death and activates the unfolded protein response through PERK/CHOP signaling in lenvatinib-resistant hepatocellular carcinoma cells.." European journal of pharmacology, vol. 1006, 2025, pp. 178115.
PMID 40912516

Abstract

[BACKGROUND] This study seeks to provide preclinical evidence demonstrating the potential of Antrocinol, a derivative of antrocin derived from the active compound of Antrodia cinnamomea, as a promising small-molecule drug candidate for overcoming drug-resistant hepatocellular carcinoma (HCC).

[METHODS] We developed Lenvatinib-resistant Huh-7 and HepG cell lines (Huh-7/LR, HepG2/LR) to evaluate their viability and apoptotic response to Antrocinol. Autophagy-dependent cell death was assessed in Huh-7/LR cells using Z-VAD-FMK and shATG5 transfection. Key UPR pathway markers were analyzed via Western blot and qRT-PCR. An orthotopic hepatocellular carcinoma mouse model was used to confirm Antrocinol's in vivo effects.

[RESULTS] Antrocinol reduced Huh-7/LR cell viability and increased apoptosis, with dose-dependent activation of caspase-3, -8, and -9. Z-VAD-FMK inhibited caspase activity but did not prevent apoptosis, indicating the presence of additional cell death mechanisms. Western blot and qRT-PCR confirmed UPR activation via upregulation of BiP/GRP78, PERK, eIF2α, ATF4, and CHOP. ATG5 knockdown abolished Antrocinol-induced cell death, confirming the role of autophagy. Combined with Lenvatinib, Antrocinol synergistically enhanced autophagy and apoptosis, inhibiting tumor growth in vitro and in vivo.

[CONCLUSION] This study provides the first evidence that Antrocinol, a novel hydroxylated derivative of antrocin, synergises with Lenvatinib to exert anti-proliferative effects on Lenvatinib-resistant HCC cells. Our results indicate that Antrocinol may enhance chemosensitivity in HCC by activating the unfolded protein response (UPR) pathway, specifically through the PERK/CHOP axis, and promoting autophagy-dependent cell death. These findings suggest that autophagy acts as a tumor-suppressive mechanism in HCC, with potential therapeutic implications for overcoming drug resistance.

MeSH Terms

Humans; Carcinoma, Hepatocellular; Liver Neoplasms; Autophagy; Unfolded Protein Response; Autophagy-Related Protein 5; Animals; Drug Resistance, Neoplasm; Signal Transduction; Transcription Factor CHOP; Mice; Quinolines; Phenylurea Compounds; Down-Regulation; eIF-2 Kinase; Hep G2 Cells; Endoplasmic Reticulum Chaperone BiP; Apoptosis; Antineoplastic Agents; Cell Line, Tumor; Xenograft Model Antitumor Assays; Cell Survival

같은 제1저자의 인용 많은 논문 (5)